Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy
Sponsor: Vertex Pharmaceuticals Incorporated
This PHASE2 trial investigates Painful Lumbosacral Radiculopathy and is currently completed. Vertex Pharmaceuticals Incorporated leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
-
Nov 2024 — Nov 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vertex Pharmaceuticals Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .